Proactive's Robin Davison publishes fresh research note on Poolbeg Pharma

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a new report on Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF), following the release of selected data from its human volunteer LPS challenge trial for lead molecule POLB 001.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  257.37
+0.00 (0.00%)
AAPL  349.21
+0.00 (0.00%)
AMD  489.19
+0.00 (0.00%)
BAC  48.57
+0.00 (0.00%)
GOOG  271.02
+0.00 (0.00%)
META  596.22
+0.00 (0.00%)
MSFT  498.30
+0.00 (0.00%)
NVDA  145.98
+0.00 (0.00%)
ORCL  110.57
+0.00 (0.00%)
TSLA  374.41
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.